Chargebacks & Fraud

GLP-1 Telehealth Sellers Face Patients Told to Check the Dispensing Pharmacy First

USA Today's October 21 guide sends GLP-1 patients to state pharmacy license lookups, PCAB or CCE accreditation checks, and FDA's compounding actions list. An analysis of what telehealth sellers can disclose about the dispensing pharmacy to build trust and limit disputes.

E-commerce 4 Internet Marketers Editorial

A daughter points to the pharmacy label on her father's prescription box as they look it up together on a snowy night.

Analysis. Sections headed “Analysis” carry EC4IM’s interpretation; the rest reports what USA Today, the Food and Drug Administration (FDA), and the Accreditation Commission for Health Care (ACHC) have published.

A USA Today guide published October 21, 2026, tells patients who get compounded GLP-1 weight-loss drugs online to look past the telehealth brand and check the pharmacy that actually makes the medicine. The article, by reporter Mary Walrath-Holdridge, walks readers through state board of pharmacy license searches, accreditation lookups, and FDA’s public list of actions against compounders. For telehealth programs that sell compounded semaglutide or tirzepatide without naming the dispensing pharmacy, that checklist describes information their patients may now go looking for before they pay.

What the USA Today guide tells patients to check

The guide tells readers to use their state board of pharmacy website to confirm the pharmacy is licensed, searching by “pharmacy” and for the pharmacy itself rather than an individual pharmacist. It notes that FDA links to every state’s database and that the National Association of Boards of Pharmacy (NABP) offers a form for questions about a pharmacy’s accreditation status.

USA Today then points readers to two compounding accreditations, PCAB and CCE, and to the ACHC directory as a way to check whether a provider is accredited. PCAB is the compounding accreditation that ACHC runs, and its public directory lets users filter by PCAB Non-Sterile Compounding, PCAB Sterile Compounding, and Hazardous Drug Handling. The Coalition for Compounding Excellence (CCE) is a separate accrediting organization. The guide also suggests asking the pharmacy for proof of accreditation or looking for it on the pharmacy’s website.

Finally, the guide sends readers to FDA’s running list of compounding inspections, recalls, and other actions, where each listing links to documents such as warning letters and inspection records. Sanjiv Lal, a pharmaceutical scientist quoted in the piece, framed the patient’s questions this way: “Who is the pharmacy? Is it properly licensed? What are its quality standards?”

The two FDA actions the guide cites

USA Today mentions FDA’s September warning letter to Empower Pharmacy. FDA’s letter to Empower Clinic Services, LLC, doing business as Empower Pharmacy, is dated September 18, 2026, and follows a November 2025 inspection of the Houston facility. FDA says the pharmacy compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin products that appear to be essentially copies of FDA-approved drugs, and it questions prescriptions generated through platforms that offer prescribers “pre-selected menu options” for the required statement of significant difference. EC4IM covered that letter in detail in FDA Warning Letter Flags Empower Pharmacy Compounded GLP-1 Telehealth Menus. A warning letter states FDA’s position; it is not a court finding.

The guide also cites a recall of compounded tirzepatide from Apothecary Pharma. FDA’s enforcement report (recall D-0036-2027) lists Tirzepatide Injection, 18 mg/mL in a 4 mL multi-dose vial, from Apothecary Pharma, LLC of Cary, North Carolina, recalled for “Lack of Assurance of Sterility.” The voluntary recall began September 24, covers 22 vials distributed nationwide in lots with beyond-use dates from October 7 through November 26, 2026, and was classified Class II on October 8. A companion entry covers one vial of the company’s NAD+ injection. FDA lists both as ongoing.

What FDA tells consumers to look for online

FDA’s consumer page on how to buy medicines safely from an online pharmacy describes a safe online pharmacy as one that always requires a prescription, gives a physical address and telephone number in the United States, has a licensed pharmacist on staff to answer questions, and is licensed with a state board of pharmacy. It sends consumers to the BeSafeRx state license locator and says, “If your online pharmacy is not listed, don’t use that pharmacy.” Among its warning signs is a pharmacy that charges for products the customer never ordered or received.

Analysis: what a GLP-1 checkout page can show

The USA Today and FDA checklists both start from the pharmacy’s name. A telehealth weight-loss site that sells a membership or consult without naming its pharmacy, whether because it uses several or changes partners, leaves that first step blank. A patient who cannot find that name before checkout cannot run any of the lookups, and a patient who first sees it on a shipping label may not connect the box to the brand that charged the card.

In EC4IM’s view, the following details could be placed on product pages and repeated at checkout and in order confirmations:

  • The dispensing pharmacy’s legal name, any “doing business as” name, and its street address and phone number.
  • The states where that pharmacy holds a license, with a link to the relevant state board lookup or FDA’s locator.
  • Whether the pharmacy operates as a 503A compounding pharmacy or a 503B outsourcing facility.
  • Any PCAB or CCE accreditation, including which service line it covers. A program shipping injectable vials would point to sterile compounding, not only non-sterile.
  • How a patient reaches a licensed pharmacist with questions.
  • What happens when the program changes pharmacies, and how existing patients will be told.

These items track FDA’s own description of a safe online pharmacy and the steps USA Today gives patients. None of them is a guarantee of quality, and a listing in FDA’s actions database does not by itself mean a pharmacy is unsafe. The value lies in letting a patient match what was purchased with who made it.

Analysis: why disclosure can reduce disputes

A card dispute does not need fraud behind it. A patient who sees a pharmacy name on a package or bank statement that never appeared on the website may decide the charge or product is wrong. A recall notice that names a pharmacy the patient has never heard of can send the same patient to the card issuer. Naming the pharmacy up front gives the customer service team an answer, and gives the merchant documentation it can cite if a dispute is filed. EC4IM has written separately about split descriptors for telehealth consult fees and pharmacy fulfillment, which addresses the billing side of the same problem.

The same details belong in a merchant application. A GLP-1 program that switches pharmacies after an FDA warning, something USA Today reports some patients have already been through, will need to show its processor the new pharmacy’s licenses and accreditation. Programs arranging telehealth card processing through Organic Payment Gateways or another specialty provider give an underwriter less to reconcile when the pharmacy in the application is the one patients see at checkout.

Where the checklist leaves telehealth sellers

USA Today’s October 21 guide gives GLP-1 patients a pharmacy-first routine: state license lookups, PCAB or CCE accreditation checks, and FDA’s compounding actions list, with the Empower warning letter and Apothecary Pharma recall as recent examples. FDA’s consumer guidance sets out similar markers of a legitimate online pharmacy. For telehealth programs, naming the dispensing pharmacy, its license states, and its accreditation on the page where patients pay lets those patients finish the check on the seller’s site, and gives payment partners and dispute teams the same record.

Sources